Regulatory product record
LENIVIA
Product identity, ingredients and source provenance from the regulatory catalogue. Linked clinical evidence has a separate review status.
Product identity
- Brand name
- LENIVIA
- DIN
- 02561816
- DPD drug code
- 106474
- Regulatory category
- APPROVED_VET_DRUG
- Market status
- MARKETED
- Route(s)
- SUBCUTANEOUS
- Pharmaceutical form(s)
- SOLUTION
- Ingredients
- IZENIVETMAB (3 MG)
- Species (DPD record)
- DOGS
- Company
- ZOETIS CANADA INC (DIN owner)
Source and provenance
- Source dataset
- health_canada_dpd_marketed
- Source snapshot date
- Not available in this source
- Source record key
- 106474
- Archive fingerprint (SHA-256)
- 85cc3ce208af3aa57018c3d14d83f90220c436baef7455384b6d48d9774e1c88
Linked clinical reference
Clinical entries are linked through the active molecule. Check their species, formulation, source and review status separately from this product record.
Clinical evidence
Dose regimens0
No dose regimens recorded for this species selection.
Adverse effects0
No adverse effects or event reports recorded for this species selection.
Literature references1
References are linked to this drug. Species applicability is not recorded here, so the species filter does not narrow this list. Imported dates do not retain their original precision; confirm dates in the original citation.
- Laboratory safety evaluations of izenivetmab, a caninized anti-nerve growth factor monoclonal antibody, for three-month alleviation of osteoarthritic pain in dogs.
Study summary not available in the imported record. Open the original citation to review the study.
Sources: PubMed, National Library of Medicine.